Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway

doi:10.4239/wjd.v16.i5.99473

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

(111)

(88)

(0)

(1)

(2286)

(2)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. May 15, 2025; 16(5): 99473
Published online May 15, 2025. doi: 10.4239/wjd.v16.i5.99473

Full Size Figure Download Figure

Figure 5 Morphological retinal changes on fundus fluorescein angiography (scale bar: 200 μm). The yellow arrow indicates vessels with increased vascular tortuosity and dilatation. The orange arrow indicates leaky vessels with increased tortuosity and dilatation. The green arrow indicates areas of retinal vascular occlusion.

Citation: Lin YT, Tan J, Tao YL, Hu WW, Wang YC, Huang J, Zhou Q, Xiao A. Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway. World J Diabetes 2025; 16(5): 99473
URL: https://www.wjgnet.com/1948-9358/full/v16/i5/99473.htm
DOI: https://dx.doi.org/10.4239/wjd.v16.i5.99473

Lin YT, Tan J, Tao YL, Hu WW, Wang YC, Huang J, Zhou Q, Xiao A. Effect of ranibizumab on diabetic retinopathy via the vascular endothelial growth factor/STAT3/glial fibrillary acidic protein pathway. World J Diabetes 2025; 16(5): 99473 [PMID: 40487605 DOI: 10.4239/wjd.v16.i5.99473]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.